FDA Commissioner Marty Makary Resigns Amid Controversy
Marty Makary has resigned as the Commissioner of the Food and Drug Administration (FDA), concluding a turbulent tenure marked by significant opposition from various stakeholders. Appointed initially as a critic of the agency, Makary faced intense backlash from both pharmaceutical developers and anti-abortion groups during his time in office. His departure follows reports in the Wall Street Journal that President Donald Trump had approved plans to dismiss him. Although President Trump publicly claimed ignorance regarding the firing plans when questioned by reporters, the resignation occurred just four days after the initial report surfaced. The article highlights the political and industrial pressures that characterized Makary's leadership, noting his involvement in recent executive actions, such as those concerning psychedelics. This event underscores the ongoing tensions between regulatory leadership, the pharmaceutical industry, and political appointees within the current administration. The resignation marks a significant shift in the FDA's direction and reflects the broader challenges faced by health regulators in navigating complex political landscapes.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection